Inventor
HARALD RAU
Inventor
DE
Overview
Patents· 19 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes37%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07KPeptides15%
Y02ATechnologies for adaptation to climate change10%
A01GHorticulture2%
A61MDevices for introducing media into, or onto, the body2%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds2%
C08JWorking-up2%
PatentTitleYear
12,565,525IL-2 conjugates202612,544,428Controlled-release CNP agonists with reduced side-effects202612,274,737PEGylated recombinant human growth hormone compounds202512,246,070Hydrogel cross-linked hyaluronic acid prodrug compositions and methods202512,239,689Controlled-release CNP agonists with low initial NPR-B activity202512,226,457Dry growth hormone composition transiently linked to a polymer carrier202512,156,917CNP prodrugs with carrier attachment at the ring moiety202412,133,883Polymeric hGH prodrugs202412,083,182Controlled-release CNP agonists with increased NEP stability202411,642,415Hydrogel cross-linked hyaluronic acid prodrug compositions and methods202311,633,487Prodrugs comprising an aminoalkyl glycine linker202311,559,482Biodegradable polyethylene glycol based water-insoluble hydrogels202311,413,351CNP prodrugs with carrier attachment at the ring moiety202211,389,511Controlled-release CNP agonists with reduced side-effects202211,389,510Controlled-release CNP agonists with low initial NPR-B activity202211,311,604Controlled-release CNP agonists with low NPR-C binding202211,298,427Prodrugs comprising a pyroglutamate linker202211,224,661Controlled-release CNP agonists with increased NEP stability202211,154,593CNP prodrugs with large carrier moieties2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to ASCENDIS PHARMA GROWTH DISORDERS AS (10)· patent assignee history
2021–2026Based in DE· patent location history
2022–2025Patents assigned to ASCENDIS PHARMA AS (5)· patent assignee history
2022Patents assigned to ASCENDIS PHARMA INC (1)· patent assignee history
2024–2025Patents assigned to ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S (3)· patent assignee history
2026Patents assigned to ASCENDIS PHARMA ONCOLOGY DIV A/S (1)· patent assignee history
2026Based in DK· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ASCENDIS PHARMA GROWTH DISORDERS AS | 10 | 2021–2026 |
| ASCENDIS PHARMA AS | 5 | 2022–2025 |
| ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S | 3 | 2024–2025 |
| ASCENDIS PHARMA INC | 1 | 2022 |
| ASCENDIS PHARMA ONCOLOGY DIV A/S | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| DE | 18 | 2021–2026 |
| DK | 1 | 2026 |